EU's IVDR Surprise: Pure Global on the Legacy Device Data Gap

This week, we dissect the European Commission's surprise March 2026 guidance document that is reshaping the IVDR transition for legacy devices. This last-minute clarification on clinical evidence requirements has invalidated the long-held assumption that a history of safe use is enough, creating an urgent documentation crisis for many established IVD products. We explore how this shift from passive to active data collection is catching even experienced manufacturers off guard. We break down the specific new demands for Performance Evaluation Reports and discuss the immediate, real-world consequences for companies who may now face significant delays and costs to keep their products on the European market. A German manufacturer of a common blood glucose monitoring system has been selling their device for 15 years. Their IVDR transition plan was set, but this new guidance means their existing post-market data is no longer sufficient. They now face a race against time to fund and execute new clinical studies, a process that could take a year and jeopardize their market presence. Key Takeaways: - Is your product's long history of safe use no longer a valid argument for IVDR compliance? - What are the new minimum data requirements for a Performance Evaluation Report (PER)? - How does this guidance impact your relationship and submission strategy with your Notified Body? - What are the three most common gaps in legacy device technical files exposed by this update? - Can your existing post-market surveillance plan be leveraged to generate the required new data? - What is the immediate financial and operational impact of having to conduct new performance studies? - How can you turn this regulatory hurdle into a competitive advantage? For more insights, contact us at [email protected] or visit https://pureglobal.com/. Explore our free resources and AI tools at https://pureglobal.ai/.